Paraneoplastic syndromes

Current Opinion in Immunology

Volumn 9, Issue 5, 1997, Pages 723-729

  Posner, Jerome B ^a   Dalmau, Josep ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CANCER VACCINE; TUMOR ANTIGEN;

ANTIBODY PRODUCTION; AUTOIMMUNITY; CANCER INHIBITION; HUMAN; IMMUNIZATION; LUNG SMALL CELL CANCER; NEUROBLASTOMA; NEUROLOGIC DISEASE; NONHUMAN; PARANEOPLASTIC SYNDROME; REVIEW; VACCINE PRODUCTION;

EID: 0030687988     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80055-6     Document Type: Article

References (58)

1. Yarbro J, Bornstein R, Mastrangelo M. Paraneoplastic syndromes. of special interest Semin Oncol. 24:1997;265-385 A comprehensive review of all paraneoplastic syndromes.
2. Brain L, Norris FH. Contemporary Neurology Symposia. 1:1965;Grune & Stratton, New York and London.
3. Brouwer B, Biemond A. Les affection parenchymateuse ducervelet et leur signification de cet organe. J Belge de Neurol Psychiatr. 38:1938;691-757.
4. Henson RA, Urich H. Cancer and the nervous system: the neurological manifestations of systemic malignant disease. 1982;Blackwell Scientific, London.
5. Mason W, Graus F, Lang B, Honnorat J, Delattre J-Y, Valldeoriola F, Antoine J, Rosenblum M, Rosenfeld M, Newsom-Davis J, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain. 120:1997;1279-1300.
6. Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiatry. 11:1948;73-87.
7. Lang B, Newsorn-Davis J. Immunopathology of the Lambert-Eaton myasthenic syndrome. Chofflon M, Steinman L, Heidelberg. Immunoneurology. 1996;Springer, Germany.
8. Yoshikawa H, Lambert E, Walser-Kuntz D, Yasukawa Y, McCormick D, Lennon V. A 17-mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis. J Immunol. 159:1997;1570-1577.
9. Palmisani M, Evoli A, Batocchi A, Provenzano C, Tonali P. Myasthenia gravis associated with thymoma: clinical characteristics and long-term outcome. Eur J Neurol. 34:1994;78-82.
10. Henson RA, Hoffman HL, Urich H. Encephalomyelitis with carcinoma. Brain. 88:1965;449-464.
11. Ridley A, Kennard C, Scholtz CL, Buttner-Ennever JA, Summers B, Turnbull A. Omnipause neurons in two cases of opsoclonus associated with oat cell carcinoma of the lung. Brain. 110:1987;1699-1709.
12. Verschuuren J, Chuang L, Rosenblum MK, Lieberman F, Pryor A, Posner JB, Dalmau J. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo associated paraneoplastic cerebellar degeneration. Acta Neuropathol. 91:1996;519-525.
13. O'Neill JH, Murray NM, Newson-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 111:1988;577-596.
14. Wilkinson PC, Zeromski J. Immunofluorescent detection of antibodies against neurons in sensory carcinomatous neuropathy. Brain. 88:1965;529-538.
15. Trotter JL, Hendin BA, Osterland K. Cerebellar degeneration with Hodgkin's disease. An immunological study. Arch Neurol. 33:1976;660-661.
16. Greenlee J, Brashear R. Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol. 14:1983;609-613.
17. Odell W. Metabolic syndromes of cancer. of special interest Semin Oncol. 24:1997;299-317 A review of paraneoplastic endocrine disorders.
18. Lang B, Vincent A. Autoimmunity to ion-channels and other proteins in paraneoplastic disorders. Curr Opin Immunol. 8:1996;865-871.
19. Voltz RD, Posner JB, Dalmau J, Graus F. Paraneoplastic encephalomyelitis: an update of the effects of the anti-Hu immune response on the nervous system and tumor. J Neurol Neurosurg Psychiatry. 63:1997;133-136.
20. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newson-Davis J. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. of outstanding interest J Neurol Sci. 147:1997;35-42 Definitive assay for antibodies which recognize P/Q type voltage-gated calcium channels and their role in diagnosing the Lambert-Eaten myastheric syndrome.
21. Takamori M, Iwasa K, Komai K. Antibodies to synthetic peptides of the alpha-1A subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. of special interest Neurology. 48:1997;1261-1265 This paper identifies epitopes on voltage-gated calcium channels that elicit the immune response in patients with Lambert-Eaton myasthenic syndrome.
22. Fukuoka T, Engel AG, Lang B, Newson-Davis J, Prior C, Wray DW. Lambert-Eaton myasthenic syndrome. I. Early morphological effects of IgG on the presynaptic membrane active zones. Ann Neurol. 22:1987;193-199.
23. Dau P, Denys E. Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol. 11:1982;570-575.
24. Kim Y. Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle Nerve. 9:1986;523-530.
25. Uchuya M, Graus F, Vega F, Rene R, Delattre J-Y. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineural autoantibodies. J Neurol Neurosurg Psychiatry. 60:1996;388-392.
26. Graus F, Vega F, Delattre J-Y, Bonaventura I, Rene R, Araiza D, Tolosa E. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with anti-neuronal autoantibodies. Neurology. 42:1992;536-540.
27. Furneaux HM, Reich L, Posner JB. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology. 40:1990;1085-1091.
28. Smitt PAES, Manley GT, Posner JB. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology. 45:1995;1873-1878.
29. Graus F, Cordon-Cardo C, Posner JB. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology. 35:1985;538-543.
30. Graus F, Elkon KB, Cordon-Cardo C, Posner JB. Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med. 80:1986;45-52.
31. Dalmau J, Graus F, Marco M. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuropathy. A clinical study of 71 patients. Medicine (Baltimore). 71:1992;59-72.
32. Szabo A, Dalmau J, Manley G, Rosenfeld M, Wong E, Henson J, Posner JB, Furneaux H. A paraneoplastic encephalomyelitis antigen contains RNA-binding domains and is homologous to elav and sex-lethal. Cell. 67:1991;325-333.
33. Ma W-J, Cheng S, Campbell C, Wright A, Furneaux H. Cloning and characterization of HuR, a ubiqultously expressed elav-like protein. J Biol Chem. 271:1996;8144-8155.
34. Marusich M, Weston J. Identification of early neurogenic cells in the neural crest lineage. Dev Biol. 149:1992;295-306.
35. Myer V, Xinhao F, Steitz J. Identification of HuR as a protein implicated in AUUUA-mediated mRNA decay. of outstanding interest EMBO J. 16:1997;2130-2139 This paper suggests that the function of HuR protein, and by implication of other Hu proteins, is to mediate mRNA decay.
36. Graus F, Ferrer I. Analysis of a neuronal antigen (Hu) expression in the developing rat brain detected by autoantibodies from patients with paraneoplastic encephalomyelitis. Neurosci Lett. 112:1990;14-18.
37. Okano H. Two major mechanisms regulating cell-fate decisions in the developing nervous system. Dev Growth Differentiation. 37:1995;619-629.
38. Marusich M, Furneaux H, Henion P, Weston J. Hu neuronal proteins are expressed in proliferating neurogenic cells. J Neurobiol. 25:1994;143-155.
39. Campos AR, Rosen Dri Robinow SN, White K. Molecular analysis of the locus elav in Drosophila melanogaster: a gene whose embryonic expression is neuro specific. EMBO J. 6:1987;425-431.
40. Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB. The expression of the Hu (paraneoplastic encephalomyelitis sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol. 141:1992;881-886.
41. Altermatt H, Rodriguez M, Scheithauer B, Lennon V. Paraneoplastic anti-Purkinje and type I antineuronal nuclear autoantibodies bind selectively to central, peripheral, and autonomic nervous system cells. Lab Invest. 65:1991;412-420.
42. Liu S, Mezrich J, Berk J, Federici M, Dalmau J, Posner JB. Expression of Purkinje cell antigens in ovarian tumor and presence of anti-Purkinje cell antibodies in the serum of patients without paraneoplastic cerebellar degeneration. Neurology. 45:1995;A228-A229. (Suppl 4).
43. Corradi J, Yang C, Darnell J, Dalmau J, Darnell R. A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr62 to immune privileged tissues. of special interest J Neurosci. 17:1997;1406-1415 This paper suggests reasons why, despite the presence of Yo mRNA in many cells, Yo proteins are restricted to Purkinje cells.
44. Cunningham J, Graus F, Anderson N, Posner JB. Partial characterization of the Purkinje cell antigens in paraneoplastic cerebellar degeneration. Neurology. 36:1986;1163-1168.
45. Tanaka K, Tanaka M, Tsukamoto T, Uehara T, Tsuji S. Anti-Yo antibody binding to 62-, 52-, or 58-kd protein recognizes a single molecule. Neurology. 46:1996;1777-1778.
46. Dropcho EJ, Chen Y-T, Posner JB, Old LJ. Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA. 84:1987;4552-4556.
47. Fathallah-Shaykh H, Wolf S, Wong E, Posner JB, Furneaux HM. Cloning of a leucine zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA. 88:1991;3451-3454.
48. Corradi JP, Darnell RB. Evidence for an interaction of the paraneoplastic cerebellar degeneration antigen cdr2 with c-myc [abstract]. Soc Neurosci. 21:1995;487.
49. Luque FA, Furneaux HM, Ferziger R, Rosenblum MK, Wray SH, Schold SC, Glantz MJ, Jaeckle KA, Biran H, Lesser M, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 29:1991;241-251.
50. Buckanovich R, Darnell R. The neuronal RNA binding protein nova-1 recognizes specific RNA targets in vitro and in vivo. Am Soc Microbiol. 17:1997;3194-3201.
51. Buckanovich R, Posner JB, Darnell R. Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron. 11:1993;657-672.
52. Dropcho EJ. Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol. 39:1996;659-667.
53. Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet. 341:1993;21-22.
54. Graus F, Dalmau J, Rene R, Tora M, Malats N, Verschuuren JJ, Cardenal F, Vinolas N, del Muro J, Vadell C, et al. Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival. of outstanding interest J Clin Oncol. 15:1997;2866-2872 The first demonstration that low-titer paraneoplastic antibodies in patients without a paraneoplastic syndrome are associated with small tumors, a better response of the tumor to treatment and a longer survival.
55. Schwerer B. Chronic progressive motor polyneuropathy after ganglioside treatment. J Neurol Neurosurg Psychiatry. 57:1994;238.
56. Cheung N-KV, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 5:1987;1430-1440.
57. Lammie GA, Cheung N-KV, Gerald W, Rosenblum M, Cordon-Cardo C. Ganglioside GD2 expression in the human nervous system and in neuroblastomas - an immunohistochemical study. Int J Oncol. 3:1993;909-915.
58. Mor G, Singla M, Steinberg A, Hoffman S, Okuda K, Klinman D. Do DNA vaccines induce autoimmune disease? Hum Gene Ther. 8:1997;293-300.